(Q33843622)

29 July 2017

1 reference

title

Economic burden of renal cell carcinoma: Part I--an updated review (English)

1 reference

29 July 2017

1 reference

I-Wen Pan

4

0 references

author name string

Ya-Chen T Shih

1

1 reference

29 July 2017

Chun-Ru Chien

2

1 reference

29 July 2017

Ying Xu

3

1 reference

29 July 2017

Grace L Smith

5

1 reference

29 July 2017

Thomas A Buchholz

6

1 reference

29 July 2017

publication date

1 April 2011

1 reference

29 July 2017

1 reference

29 July 2017

volume

29

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

315-329

1 reference

https://scigraph.springernature.com/pub.10.2165/11586100-000000000-00000

29 July 2017

exact match

0 references

cites work

Follow-up surveillance strategies for genitourinary malignancies

1 reference

12 December 2020

Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma.

1 reference

12 December 2020

Laparoscopic and open partial nephrectomy: cost comparison with analysis of individual parameters

1 reference

12 December 2020

Years of life lost (YLL) from cancer is an important measure of population burden--and should be considered when allocating research funds

1 reference

12 December 2020

Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis

1 reference

12 December 2020

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

12 December 2020

Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.

1 reference

12 December 2020

Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes

1 reference

12 December 2020

The burden of illness associated with renal cell carcinoma in the United States.

1 reference

12 December 2020

Patient time costs associated with cancer care

1 reference

12 December 2020

Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma

1 reference

12 December 2020

Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Economic burden of renal cell carcinoma in the US: Part II--an updated analysis

1 reference

12 December 2020

Guidelines on renal cell cancer

1 reference

12 December 2020

Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?

1 reference

12 December 2020

Two new drugs for renal cell carcinoma

1 reference

12 December 2020

Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology

1 reference

12 December 2020

Analysis of complications following partial and total nephrectomy for renal cancer in a population based sample

1 reference

12 December 2020

Radiofrequency ablation in the treatment of kidney cancer.

1 reference

12 December 2020

Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US.

1 reference

12 December 2020

Temsirolimus (Torisel) for advanced renal cell carcinoma

1 reference

12 December 2020

Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma

1 reference

12 December 2020

The National Institute of Health and Clinical Excellence rejects new treatments for renal cell cancer: Cinderella's invitation is cancelled

1 reference

12 December 2020

Watchdog set to reject four drugs for kidney cancer on the NHS.

1 reference

12 December 2020

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

1 reference

12 December 2020

Cost analysis of open, laparoscopic, and percutaneous treatment options for nephron-sparing surgery

1 reference

12 December 2020

1 reference

12 December 2020

Do the results of the new trials change the standard treatment of metastatic renal cell cancer?

1 reference

12 December 2020

Renal tumor natural history: the rationale and role for active surveillance

1 reference

12 December 2020

Welcome clinical leadership at NICE

1 reference

12 December 2020

A population-based case-control study of occupation and renal cell carcinoma risk in Iowa

1 reference

12 December 2020

Alcohol drinking and renal cell carcinoma in Canadian men and women

1 reference

12 December 2020

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

1 reference

12 December 2020

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

12 December 2020

Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.

1 reference

12 December 2020

NICE recommends kidney cancer drug it previously rejected on cost grounds

1 reference

12 December 2020

Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis

1 reference

12 December 2020

Dietary vitamin C, E, and carotenoid intake and risk of renal cell carcinoma

1 reference

12 December 2020

Time costs associated with informal caregiving for cancer survivors

1 reference

12 December 2020

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib

1 reference

12 December 2020

Estimating health care costs related to cancer treatment from SEER-Medicare data

1 reference

12 December 2020

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review

1 reference

12 December 2020

Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland

1 reference

12 December 2020

Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma.

1 reference

12 December 2020

Cost of care for elderly cancer patients in the United States.

1 reference

12 December 2020

Urologic diseases in America Project: analytical methods and principal findings.

1 reference

12 December 2020

Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.

1 reference

12 December 2020

Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients

1 reference

12 December 2020

Targeted drugs for metastatic renal cell carcinoma

1 reference

12 December 2020

Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.

1 reference

12 December 2020

Application of IL-2 and other cytokines in renal cancer

1 reference

12 December 2020

Dimensions Publication ID

Identifiers

1078362977

0 references

1 reference